{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:36:47Z","timestamp":1791722207384,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.transproceed.2018.02.060","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T12:31:04Z","timestamp":1528806664000},"page":"1243-1248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study"],"prefix":"10.1016","volume":"50","author":[{"given":"S.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Edelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.02.060_bib1","series-title":"Diseases of the Kidney and Urinary Tract. 2","first-page":"502","article-title":"Polycystic kidney disease","author":"Ecder","year":"2007"},{"key":"10.1016\/j.transproceed.2018.02.060_bib2","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: the changing face of clinical management","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2018.02.060_bib3","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.02.060_bib4","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1046\/j.1523-1755.2001.00985.x","article-title":"Pain management in polycystic kidney disease","volume":"60","author":"Bajwa","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2018.02.060_bib5","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1523-1755.2004.00921.x","article-title":"Pain patterns in patients with polycystic kidney disease","volume":"66","author":"Bajwa","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2018.02.060_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1053\/j.ackd.2010.01.005","article-title":"Evaluation and management of pain in autosomal dominant polycystic kidney disease","volume":"17","author":"Hogan","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.transproceed.2018.02.060_bib7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","article-title":"Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study","volume":"63","author":"Miskulin","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2018.02.060_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1432-2277.2011.01237.x","article-title":"Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study","volume":"24","author":"Jacquet","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2018.02.060_bib9","doi-asserted-by":"crossref","first-page":"c42","DOI":"10.1159\/000334429","article-title":"Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: a single-centre 40-year study","volume":"120","author":"Haynes","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.transproceed.2018.02.060_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0954-6820.1985.tb01656.x","article-title":"Volume changes in polycystic kidneys during chronic dialysis and after renal transplantation","volume":"217","author":"Thaysen","year":"1985","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.transproceed.2018.02.060_bib11","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/TP.0b013e318246f910","article-title":"Kidney volume changes in patients with autosomal dominant polycystic kidney disease after renal transplantation","volume":"93","author":"Yamamoto","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.02.060_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfv227","article-title":"Volume regression of native polycystic kidneys after renal transplantation","volume":"31","author":"Jung","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2018.02.060_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/ndt\/12.7.1431","article-title":"Autosomal dominant polycystic kidney disease in a kidney transplant population","volume":"12","author":"Hadimeri","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 6","key":"10.1016\/j.transproceed.2018.02.060_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ndt\/11.supp6.24","article-title":"Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease","volume":"11","author":"Pirson","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2018.02.060_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneph.2014.104","article-title":"Renal transplantation in autosomal dominant polycystic kidney disease","volume":"10","author":"Kanaan","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.transproceed.2018.02.060_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajt.12579","article-title":"OPTN\/SRTR 2012 annual data report: kidney","volume":"14","author":"Matas","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.02.060_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.2010.250","article-title":"Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease","volume":"78","author":"Zafar","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2018.02.060_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2018.02.060_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMra022161","article-title":"Polycystic kidney disease","volume":"350","author":"Wilson","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.02.060_bib20","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.02.060_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2018.02.060_bib22","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.transproceed.2018.02.060_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2018.02.060_bib24","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.02.060_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00004728-200007000-00019","article-title":"Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease","volume":"24","author":"Bae","year":"2000","journal-title":"J\u00a0Comput Assist Tomogr"},{"key":"10.1016\/j.transproceed.2018.02.060_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2018.02.060_bib27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2018.02.060_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.transproceed.2018.02.060_bib29","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2018.02.060_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.transproceed.2013.10.040","article-title":"Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials","volume":"46","author":"Liu","year":"2014","journal-title":"Transplant Proc"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518302082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518302082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T11:34:27Z","timestamp":1635507267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134518302082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0041134518302082"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.02.060","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.02.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}